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Background: Processing of HIV-1 Gag/Gag-Pro-Pol polyprotein by viral protease is an essential step to produce infectious
virus particle.
Results: Processing of CA/SP1, SP1/NC, and SP2/p6 sites by HIV-1 protease are affected by context.
Conclusion: Complex substrate interactions beyond the active site of the enzyme define HIV-1 processing rate.
Significance: This study helps to understand role of context outside cleavage sites in HIV-1 processing.
Processing of the human immunodeficiency virus type 1
(HIV-1) Gag and Gag-Pro-Pol polyproteins by the HIV-1 prote-
ase (PR) is essential for the production of infectious particles.
However, the determinants governing the rates of processing of
these substrates are not clearly understood. We studied the
effect of substrate context on processing by utilizing a novel
protease assay in which a substrate containing HIV-1 matrix
(MA) and the N-terminal domain of capsid (CA) is labeled with
a FlAsH (fluorescein arsenical hairpin) reagent.When the seven
cleavage sites within the Gag and Gag-Pro-Pol polyproteins
were placed at the MA/CA site, the rates of cleavage changed
dramatically compared with that of the cognate sites in the nat-
ural context reported previously. The rate of processing was
affected the most for three sites: CA/spacer peptide 1 (SP1)
(≈10-fold increase), SP1/nucleocapsid (NC) (≈10–30-fold
decrease), and SP2/p6 (≈30-fold decrease). One of two multi-
drug-resistant (MDR) PR variants altered the pattern of proc-
essing rates significantly. Cleavage sites within the Pro-Pol
region were cleaved in a context-independent manner, suggest-
ing for these sites that the sequence itself was the determinant of
rate. In addition, a chimera consisting of SP1/NC P4–P1 and
MA/CA P1–P4 residues (ATIM2PIVQ) abolished processing
by wild type and MDR proteases, and the reciprocal chimera
consisting of MA/CA P4–P1 and SP1/NC P1–4
(SQNY2IQKG) was cleaved only by one of the MDR proteases.
These results suggest that complex substrate interactions both
beyond the active site of the enzyme and across the scissile bond
contribute to defining the rate of processing by the HIV-1 PR.
Proteolytic cleavage of the HIV-1 polyproteins Gag andGag-
Pro-Pol by the viral protease (PR)2 is an essential step to pro-
duce an infectious virus particle. Proteolysis occurs concomi-
tantly with budding of the virus particle, and this processing
releases mature virion proteins (matrix (MA), capsid (CA),
spacer peptide 1 (SP1), nucleocapsid (NC), spacer peptide 2
(SP2), and p6) from Gag, and in addition the viral enzymes,
protease, RT, and integrase (IN) from Gag-Pro-Pol (1). This
event is highly regulated by a number of elements such as the
substrate sequence/conformation, the presence of spacer pep-
tide domains, the interaction with RNA, and the context of the
cleavage sites (2–7). However, the precise mechanisms govern-
ing the rates of the cleavage events are not fully understood.
The processing sites in the Gag polyprotein are cleaved at
different rates, resulting in sequential Gag processing during
the maturation process (3, 6, 8–10). In an experimental setting
where the Gag polyprotein was synthesized in vitro and cleav-
age was initiated with the addition of purified protease, the
initial cleavage occurs at the SP1/NC site and the cleavages at
theMA/CAandSP2/p6 sites follows at an10-fold slower rate.
The slowest cleavages then occur at the CA/SP1 and NC/SP2
(3). The cleavage at the CA/SP1 site is the slowest, with a cleav-
age rate of about 400-fold slower than that of the initial cleavage
(3). A similar system using Gag-Pro-Pol has shown that the
cleavage at theRT/IN site occurs at a rate similar to the cleavage
at the MA/CA site, and cleavages at the two sites flanking the
PR (TF/PR and PR/RT) occur at the final stage of the Gag-Pro-
Pol processing (9). The cleavage event at each site takes place
independently of the other sites when protease is provided in
trans with the exception of the cleavage at the CA/SP1 site,
which showed enhanced cleavage when the initial cleavage
event at the downstream SP1/NC site was blocked by a muta-
tion, M377I (3). Thus, the processing at the CA/SP1 site is neg-
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atively regulated by the presence of the SP1domain after release
from the NC domain, which may create an unfavorable envi-
ronment for cleavage by the HIV-1 protease.
The viral protease is a homodimer with the active site at the
dimer interface (11–13), whereas the cleavage sites in the Gag
and Gag-Pro-Pol polyproteins are structurally asymmetric,
sharing little amino acid sequence homology (14). Crystallo-
graphic studies using peptides corresponding to the cleavage
sites within the Gag and Gag-Pro-Pol polyproteins have
revealed that theHIV-1 protease achieves its substrate specific-
ity in part by recognizing a conserved shape rather than a par-
ticular amino acid sequence (15). In these studies, all of the
peptide substrates were shown to adopt an asymmetric
extended -strand conformation when bound in the active site
of the enzyme creating a consensus volume termed the “sub-
strate envelope.” Recently, Ozen et al. (16) demonstrated how a
particular substrate that fits within the substrate envelope is
influenced by both substrate dynamics and size. In this study,
the volume of theCA/SP1,NC/SP2, and SP2/p6 substrates pro-
truded beyond the substrate envelope more than expected
based on their size. These substrates were highly dynamic,
resulting in large deviations from the crystal structure and a
worse fit within the substrate envelope. Consistent with their
slow rate of cleavage, the CA/SP1 and NC/SP2 substrates were
shown to score as being themost dynamic among the substrates
analyzed (16).
The order of cleavage obtained from the kinetic studies using
peptide substrates corresponding to the cleavage sites in Gag
and Gag-Pro-Pol differs from the order of cleavage in the con-
text of the full-length Gag polyprotein (3, 9, 17–22). Further-
more, the peptide substrates used in different studies did not
reproduce the same order of cleavage (19, 21, 22), suggesting
that additional determinants beyond amino acid sequence and
local secondary structure of the cleavage sites are involved in
Gag and Gag-Pro-Pol processing. One clear example is that in
the context of full-length Gag polyprotein, the cleavage of the
CA/SP1 is negatively affected by the initial cleavage at the
SP1/NC site (3). There are also reported differences in both the
order and the cleavage rate of peptide substrates when different
lengths of peptides were used, implying that amino acids out-
side the active site groove may play a role in Gag and Gag-Pro-
Pol cleavage. One example of the importance of the context
surrounding cleavage sites in HIV-1 Gag processing was dem-
onstrated in the study by Tritch et al. (5) using a protein sub-
strate derived from the Gag polyprotein. When the P4–P4
residues of the MA/CA site were replaced with the P4–P4
residues of the SP1/NC site, the rate of cleavage was enhanced
compared with that of the MA/CA site; however, the extent of
enhancement was shown to be far less than that expected com-
pared with cleavage of this site in its normal setting, suggesting
that the context outside the local cleavage site is also involved in
the efficient cleavage of the SP1/NC site. It has also been
reported that processing site context, specifically sequences
flanking the C terminus of the protease, can affect enzyme
activity (23).
Although the context outside of the cleavage site has been
suggested to play a role as a determinant for the substrate spec-
ificity of theHIV-1 protease, studies regarding contextual influ-
ences onHIV-1 processing have not been addressed extensively
using folded protein substrates. Therefore, to examine the
effect of context onHIV-1 processing, we conducted a compar-
ative analysis of the Gag and Gag-Pro-Pol cleavage sites in a
heterologous environment using a sensitive HIV-1 protease
assay. In this assay, the MA/CA fusion protein modified with
several alterationswas used as a substrate. A tetracysteinemotif
(CCGPCC) was introduced within the N-terminal domain of
CA to allowbinding of the FlAsH (fluorescein arsenical hairpin)
reagent (24–26). In addition, to differentiate the size of the
cleavage products from two pooled substrates, a GST tag was
fused to the N terminus of MA, and the C-terminal domain of
CA was truncated. By utilizing this substrate labeled with
FlAsH reagent, we were able to measure specific proteolysis in
gel-based assays as a function of HIV-1 protease cleavage.
When the residues P4–P4 of the cleavage sites within Gag and
Gag-Pro-Pol were placed at the MA/CA site, we observed
changes in the order of the cleavage rate, indicating that the
context outside the P4–P4 residues plays a crucial role for
efficientGag andGag-Pro-Pol cleavage. Changes in the order of
the cleavage rates were also seen with a multi-drug resistant
(MDR) protease. Combining the P4–P1 residues from the
SP1/NC site and the P1–P4 residues from the MA/CA site
resulted in a chimeric substrate that was not significantly
cleaved by any of the proteases tested in this study, whereas the
reciprocal construct was selectively cleaved by one of theMDR
proteases but not by the wild type protease. These results indi-
cate that more complex interactions than just those of the sub-
strate amino acids within the active site of the protease are
required for efficient Gag and Gag-Pro-Pol cleavage by the
HIV-1 protease and that this new series of folded protein sub-
strates offers a tool to examine protease specificity.
EXPERIMENTAL PROCEDURES
Constructs—The primers to construct plasmids used in this
study were designed so that a His tag was introduced at the N
terminus of each protein. The plasmid pARKz1k1–5LTRgag,
containing a fragment of 5 LTR and the gag region of pNL-CH,
an infectiousmolecular clone derived from the pNL4-3 clone of
HIV-1 (27), was used as a template to amplify the full-length
MA/CA coding region by PCR. The PCR product was digested
with NdeI, which was introduced in the PCR primers, and
cloned into theNdeI site of pET30b (Novagen,Madison,WI) to
generate the pMA/CAprecursor plasmid. A tetracysteinemotif
(CCGPCC) was introduced within the N-terminal domain of
CA (His-87–Ala-92) by site-directedmutagenesis following the
QuikChange method (Stratagene, La Jolla, CA) to create the
final pMA/CA plasmid (see Fig. 1A). For pMA/CA, two over-
lapping PCR fragments, one containing the coding region for a
GST tag amplified from pET41b (Novagen) and the other con-
taining the full-length MA/CA coding region amplified from
pMA/CA, were used in an overlapping extension PCR. The
resulting PCR product was cloned into theNdeI site of pET30b,
and then the C-terminal domain of CA was truncated by sub-
stituting Ser-278 with a stop codon. The pMA/CA-noTCwas
created in the same way that the pMA/CA was generated
except that the full-lengthMA/CA coding regionwas amplified
from pARKz1k1–5LTRgag to exclude the tetracysteine motif
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from the CA region. To generate pMA/CA-Y132I, a Y132I
mutation was introduced at the P1 position of the MA/CA
cleavage site by site-directedmutagenesis using the pMA/CA
as the template. For the constructs shown in Fig. 1B, eight
codons representing the P4–P4positions of theMA/CAcleav-
age site in the pMA/CA were replaced with either the equiv-
alent codons from the CA/SP1, SP1/NC, NC/SP2, SP2/p6,
TF/PR, PR/RT, RT/IN, or chimeric cleavage sites using over-
lapping extension PCR. The SP1/NC P4–1 was generated by
overlapping extension PCR so that the P4–P1 residues are
derived from the SP1/NC cleavage site and the P1–P4 resi-
dues are derived from the MA/CA cleavage site. The SP1/NC
P1–4 was generated in the same way that the SP1/NC P4–1
was generated except that the P4–P1 residues are derived from
the MA/CA cleavage site and the P1-P 4 residues are derived
from the SP1/NC cleavage site. The structure of each of the
constructs was confirmed by DNA sequence analysis.
Expression and Purification of HIV-1 PR Substrates—Expres-
sion of recombinant proteins in Escherichia coli BL21 (DE3)
was carried out by a modified version of established protocols
(28, 29). Briefly, recombinant proteins were expressed in Mag-
icMedia (Invitrogen) for 7 h, and the cells were collected by
centrifugation. The cell pellet was lysed in Tris-buffered saline
(25 mM Tris base, 3 mM KCl, and 140 mM NaCl) at pH 7.5 with
1mMDTT and 1% Triton X-100 and then sonicated. Following
clarification by centrifugation, the recombinant proteins con-
taining a His6 tag at the N termini were purified from the solu-
ble fraction by affinity chromatography using a nickel-chelating
column (Novagen). The purified recombinant proteins were
dialyzed against 20mM sodium acetate (pH 7.0), 1 mM EDTA, 2
mM DTT, and 10% glycerol (30). Protein concentrations were
determined by using the Bradford assay (Bio-Rad, Hercules,
CA), and the purity of the purified proteins was analyzed by
protein staining using SimplyBlue SafeStain (Invitrogen) after
SDS-PAGE (31).
Protease Expression and Purification—The HIV-1 protease
was expressed in E. coli TAP 106 cells and purified from inclu-
sion bodies as previously described (32). Briefly, the inclusion
body centrifugation pellet was dissolved in 50% acetic acid fol-
lowed by another round of centrifugation to remove impurities.
Size exclusion chromatography was used to separate high
molecular weight proteins from the protease. The protein was
refolded in 50mM sodium acetate at pH 5.5, 5% ethylene glycol,
10% glycol, and 5 mM DTT.
FlAsH Labeling Reactions—The FlAsH reagent (Invitrogen)
was incubated overnight (15 h)with theMA/CA-protein sub-
strate in a 1:1 molar ratio at room temperature (33) in proteol-
ysis buffer (50 mM sodium acetate, pH 7.0, 150 mMNaCl, 1 mM
EDTA, 2 mM 2-mercaptoethanol, and 10% glycerol). A total
concentration of 6 M of the protein substrates was used for
FlAsH labeling in a total volume of 228 l.
Gel-based Protease Assay by HIV-1 PR—To compare proc-
essing efficiency of the heterologous substrates (cleavage sites
introducedwithin theMA/CA site) with theMA/CA substrate,
3 M of each of two substrates (a heterologous substrate plus
the MA/CA substrate) was labeled with 6 M FlAsH reagent in
a tube with a total volume of 228 l. An aliquot of 24 l was
taken for the 0-min time point before the addition of 0.1 M
HIV-1 PR to the substrate. Proteolysis was performed at 30 °C,
and aliquots of 24 l were taken at various time points, and the
reaction was stopped by adding 4 SDS-PAGE loading buffer.
After the last time point, the protein in the aliquots was
resolved by SDS-PAGE without a boiling step. The concentra-
tion of a reducing reagent, 2-mercaptoethanol, in the SDS-
PAGE loading buffer was kept at 2 mM to keep the FlAsH rea-
gent coupled to the substrate. The gels were briefly rinsed with
water, and the fluorescently labeled protein bands were visual-
ized by fluorescence imaging using a Typhoon 9400 (GE
Healthcare/Amersham Biosciences) with excitation at 488 nm
and emission at 526 nm. The relative quantitation of the visu-
alized protein bands was performed by using the image analysis
software ImageQuant TL (GE healthcare). To calculate the rel-
ative rate of individual cleavage site, the percentage amount of
the cleavage products within the linear range was plotted as a
function of the time. Briefly, the time points representing either
less than or equal to 20% cleavage were used for linear regres-
sion, and then the slope value of the individual cleavage site was
used to determine cleavage rate relative to the MA/CA site.
Unless specified, all of the labeling and proteolysis reactions
were performed at pH 7.0 because of the dependence of the
FlAsH reagent on pH. For binding specificity of the FlAsH rea-
gent to a tetracysteine motif, the labeling reaction of the 3 M
substrate (MA/CA orMA/CA-noTC) was performed in the
absence or presence of 3 M FlAsH reagent at pH 7.0. Proteol-
ysis was performed in the absence or presence of the 2 M
HIV-1 PR at 30 °C for 3 h, and the resulting protein products
were subjected to SDS-PAGE. The fluorescent protein bands
were visualized by Typhoon 9400, and the same gel was stained
with SimplyBlue SafeStain for Coomassie staining. For the
effect of pH on HIV-1 PR activity, 3 M substrate (MA/CA)
was used for labeling reaction at pH5.5, 6.0, 6.5, or 7.0 following
the protocol described above.
Estimation of vanderWaals Potential andHydrogenBonding—
For the structural analyses, crystal structures were used when
available. When an experimentally determined structure was not
available, the structure of the substrate complex that was most
similar in sequence to the target substrate was used as the tem-
plate. To this template, the mutations were introduced in silico
using Maestro from Schrodinger Suite 2011 (Schrodinger, Port-
land, OR). All of the structures (experimental and modeled) were
prepared for the structural analyses using the Protein Preparation
Wizard ofMaestro. In the preparation step, hydrogen atomswere
added, and the missing side chains were filled in and refined. The
hydrogen bonding networkwas optimized at neutral pHusing the
exhaustive sampling option. Orientations of the crystallographic
waters were also sampled for the optimal hydrogen bonding net-
work. Energy minimization was performed on the coordinates of
thehydrogen atomsonly, followedby a second restrainedminimi-
zation on the whole system until rootmean square deviation con-
verged to 0.3 Å for crystal structures and 0.5 Å for the modeled
structures. After preparation, each structure was analyzed for the
protease-substrate hydrogen bonds and van der Waals contacts.
The total number of hydrogen bonds was counted by using the
default geometric criteria in Maestro (2.5 Å maximum distance,
120° minimum donor angle, and 90° minimum acceptor angle).
Protease-substratevanderWaals interactionswerecalculatedbya
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simplified Lennard-Jones potential function as described in detail
elsewhere (16).
RESULTS
Design of Substrates for Gel-based HIV-1 Protease Assay
Employing FlAsH Reagent—To study the effect of context/en-
vironment on the processing of the HIV-1 Gag and Gag-Pro-
Pol cleavage sites by the HIV-1 PR, we developed a protease
assay in which a Gag protein substrate is labeled with a FlAsH
reagent, a nonfluorescent biarsenical derivative of fluorescein
that becomes fluorescent upon binding to its target (26). In this
assay, a folded MA/CA protein containing an intact MA/CA
cleavage site was used as a prototype substrate with the follow-
ing modifications. A tetracysteine motif (CCGPCC) was intro-
duced into a surface loop region within the N-terminal domain
of CA (amino acids 87–92), near the position previously used to
label intact virus (34), to allow for FlAsH reagent binding,
resulting in a substrate designated as MA/CA (Fig. 1A). The
substrate MA/CA (GST-MA-CACTD) was made by fusing
a GST tag to theN terminus ofMA tomake the substrate larger
and truncating theC-terminal domain (CTD) ofCA to decrease
the size of the cleaved labeled product (Fig. 1A). TheMA/CA-
noTC is the same substrate as the MA/CA except that the
MA/CA-noTC lacks the tetracysteinemotif needed for FlAsH
reagent binding. To introduce a heterologous cleavage site into
the context of the MA/CA cleavage site, the MA/CA cleavage
site withinMA/CAwas replaced with each of the seven cleav-
age sites from the Gag and Gag-Pro-Pol polyprotein, individu-
ally generating substrates with the cleavage sites CA/SP1, SP1/
NC, NC/SP2, SP2/p6, TF/PR, PR/RT, and RT/IN, as shown in
Fig. 1B. Because of the differences in size of the two substrates,
MA/CA and MA/CA, and the labeled cleavage products, CA
and CA, this strategy enables us to perform proteolysis reac-
tions in the presence of the MA/CA substrate as an internal
control and to resolve the cleavage products by SDS-PAGE.
Efficient Processing of MA/CA by HIV-1 PR and Specific
Binding of FlAsH Reagent to Tetracysteine Motif—Because the
MA/CA fusion proteinwasmodified for the assay, we first com-
pared the efficiency of cleavage of the altered substrate
MA/CA (56 kDa) with that of the MA/CA protein (40
kDa) in the gel-based assay, placing equal molar amounts of
each substrate into the reaction. Because the two substrates and
their cleavage products differ in size and hence can be resolved
by SDS-PAGE,wewere able tomix the two substrates and carry
out the protease assay together. Fig. 2A shows the cleavage
products over a 3-h time period visualized by fluorescence
imaging. The N-terminal domain of CA harbors the tetracys-
teine motif where the FlAsH reagent binds; thus only the pro-
teins containing the N-terminal domain of CA are detected by
fluorescence imaging. Both substrates were processed by the
HIV-1 protease at a similar rate over time as assessed by the
band intensity of the cleaved CA products, the full-length CA
released from MA/CA, and the CA (15 kDa) released from
MA/CA (Fig. 2, A and B). Thus, the alterations made to the
MA/CA protein did not affect its cleavage efficiency by the
protease nor result in significant artifactual degradation of the
protein or cleavage at fortuitous sites. We also tested cleavage
efficiency of the SP2/p6 site (a site that is cleaved slowly, see
below) in both substrates, MA/CA and MA/CA, and we
observed very similar cleavage rates with each substrate (data
not shown), confirming that the alterationswemade toMA/CA
did not affect cleavage at the MA/CA site. The faint band run-
ning slightly slower than CA protein, noted with an arrow in
Fig. 2A, seems to be anunknown contaminant specifically of the
MA/CA prep that is labeledwith the FlAsH reagent; its nature
is unclear because it is present in the uncleaved prep, and the
band intensity does not change in the presence of protease.
Studies done in vivo and in vitro have previously demon-
strated that the FlAsH reagent binds a tetracysteine motif with
high affinity and specificity (26), and proteins labeled with the
FlAsH reagent have been analyzed by SDS-PAGE (24). How-
ever, in this previous report the detection of such protein bands
in a gel was not optimal, which may have been due to the use of
crude E. coli lysates for FlAsH labeling. To test the specificity of
the FlAsH reagent binding to the tetracysteine motif, two sub-
strates, one harboring a tetracysteine motif (MA/CA) and the
other lacking a tetracysteine motif (MA/CA-noTC), were
visualized by both Coomassie staining and fluorescence imag-
ing in the absence or presence of FlAsH reagent and protease
cleavage (Fig. 2C). In the presence of protease, Coomassie Blue
staining showed that bothMA/CA andMA/CA-noTC gen-
FIGURE 1. Schematic diagram of MA/CA constructs. A, the structure of the
constructs in backbone of the E. coli expression vector pET30b. The parental
construct, MA/CA, contains an intact MA and CA domain. The constructs
MA/CA, MA/CA-noTC, and MA/CA-Y132I include alterations with the
addition of GST tag at the N terminus of the MA domain and the truncation of
C-terminal domain of CA. The MA/CA-Y132I has an Ile substitution at the P1
position of the MA/CA cleavage site that blocks cleavage at the site. The
tetracysteine motif (CCGPCC) is introduced within the N-terminal domain of
CA, and the hatched boxes at the N terminus represent the His6 tag. The cleav-
age site between MA and CA is indicated. B, Gag and Gag-Pro-Pol cleavage
sites in the context of the MA/CA. The amino acid sequences of the cleavage
sites within the Gag and Gag-Pro-Pol region substituting the P4 –P4 residues
of the MA/CA site (SQNY2PIVQ) in the MA/CA construct are shown. The
chimeric SP1/NC P4 –1 contains P4 –P1 derived from the SP1/NC site and P1–
P4 derived from the MA/CA site, whereas the SP1/NC P1– 4 contains P4 –P1
derived from the MA/CA site and P1–P4 derived from the SP1/NC site.
Effect of Context on HIV-1 Gag Processing
13282 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 16 • APRIL 13, 2012
erated the same two cleavage products, p40 GST-MA and the
p15 truncated CA protein, CA. The same gel visualized by
fluorescence imaging revealed that only the bands (indicated by
the asterisks) of the proteins harboring a tetracysteine motif
had the FlAsH reagent. The fact that the MA/CA-noTC pro-
tein did not show any nonspecific binding of the FlAsH reagent
to the protein confirms that the interaction between the tetra-
cysteine motif and the FlAsH reagent is highly specific. The
band intensity of FlAsH-labeled protein visualized by fluores-
cence imaging depends on the number of the molecules rather
than the size of the molecules, providing a broad and linear
detection range. When we compared the sensitivity of detec-
tion between severalmethods, the gel-based assay using FlAsH-
labeled protein showed sensitivity of detection comparable
with that of silver staining (data not shown). Finally, to show
specificity of protease cleavage, we combined thewild type sub-
strate with a substrate where the P1 tyrosine was replaced with
isoleucine to block protease cleavage. When these substrates
were incubated together with protease, only the substrate with
the wild type cleavage site was cleaved (Fig. 2D).
Lower pH (6.0) Is Not Optimal for Protease Cleavage of Pro-
tein Substrate MA/CA—The gel-based protease assay was
performed at pH 7.0 because the FlAsH reagent becomes non-
fluorescent at pH values below 6.0 (35). However, most enzy-
matic analyses of the HIV-1 protease using peptide substrates
have been performed at lower pH, typically near pH 5.0, and the
rates of cleavage of the MA/CA and CA/SP1 sites have been
shown to be accelerated at pH 5.0 compared with pH 7.0 when
peptide substrates were used (3). Although HIV-1 protease
assays using full-length Gag polyprotein have been performed
at pH7.0 (3, 5), the cleavage rate of theCA/SP1 in the context of
the full-length Gag polyprotein was shown to be significantly
increased at lower pH relative to cleavage ofMA/CA (3). There-
fore, to examine whether the processing of the MA/CA sub-
strate by theHIV-1 protease at pH7.0 is optimal comparedwith
the cleavage at pH 5.5, the enzyme activity of the protease at
different pH values, pH 5.5, 6.0, 6.5, and 7.0, was compared.
Surprisingly, in the context of a large protein substrate, the
protease cleaved the MA/CA site more efficiently at pH values
higher than 6.0, although no significant difference was seen
between pH 6.0 and 7.0 (Fig. 3, A and B). As expected, band
intensity was uniformly decreased at the pH 5.5 because of the
FlAsH reagent becoming nonfluorescent at lower pH (for both
the precursor and the product). In contrast with previous stud-
ies using peptide substrates, the cleavage rate of the protein
substrate by the proteasewas dramatically accelerated at higher
pH (approximately a 10-fold increase at pH values above 6.0)
comparedwith the rate of cleavage observed at pH 5.5 (Fig. 3C).
Thus, optimal pH in this protease assay usingMA/CA substrate
is between 6.5 and 7.0, which is more consistent with physio-
logical pH.
Impact of Heterologous Context on Cleavage Rates of Process-
ing Sites within Gag and Gag-Pro-Pol Polyproteins—The proc-
essing sites in the Gag polyprotein are cleaved at different rates
resulting in sequential Gag processing during the maturation
process to produce an infectious virion. In a previous in vitro
study (3, 9, 10), the processing rates of the different cleavage
sites in the Gag precursor gave the following relative rates of
cleavage (setting the MA/CA cleavage rate to 1): SP1/NC 14X,
SP2/p6 1.6X, MA/CA 1X, and CA/SP1 and NC/SP2 0.04X. In
the current study, we replaced the eight amino acids (P4–P4)
at theMA/CA cleavage site within theMA/CA substrate with
the cleavage site sequences from the other Gag and Gag-Pro-
Pol cleavage sites: CA/SP1, SP1/NC, NC/SP2, SP2/p6, TF/PR,
FIGURE 2. Efficient processing of the MA/CA by HIV-1 PR and specific binding of the FlAsH reagent to the tetracysteine motif. A, both substrates
MA/CA and MA/CA were labeled with the FlAsH reagent in the same reaction, and proteolysis of the mixed substrates was performed at 30 °C by adding 0.1
M HIV-1 PR. Equal molar amounts of the two substrates were used, and the same molar ratio between the FlAsH reagent and total amounts of the protein were
used. Aliquots were taken at the various time points shown above each lane and resolved by SDS-PAGE. The aliquot for the 0-min time point was taken before
the enzyme was added. Fluorescently labeled proteins were visualized by fluorescence imaging. Filled arrowheads indicate MA/CA substrate and its cleavage
product (CA), and open arrowheads indicate MA/CA substrate and its cleavage product (CA). B, the band intensity of the cleavage products, CA and CA, in
A was quantified and plotted as a function of the time. C, the substrate MA/CA carrying a tetracysteine motif and the MA/CA-noTC lacking a tetracysteine
motif were subjected to labeling reactions in the absence or presence of FlAsH reagent. After the labeling reaction, the proteolysis reaction was performed in
the absence or presence of 2 M HIV-1 PR. The cleavage pattern of the substrates is visualized by Coomassie Blue staining (left) and fluorescence imaging (right).
The bands indicated with an asterisk are visualized by fluorescence imaging. D, cleavage of the MA/CA-Y132I is displayed over time to show specific
processing of the MA/CA site by the HIV-1 PR.
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PR/RT, or RT/IN. Although no changes were made in amino
acid sequences required for processing, the transposition of
these sequences resulted in the cleavage sites being placed in a
heterologous environment in the context of the Gag precursor.
If the context outside of each cleavage site plays a role in deter-
mining cleavage rates, we would expect to see changes in the
relative order of Gag cleavage. In this design, the initial rate of
cleavage defines the specificity constant (kcat/Km), and the dif-
ference in the initial rate of the two different substrates, when
present at equal concentrations, defines the difference in the
specificity constant. In the following experiments the initial
rate of cleavage of the wild type MA/CA substrate was set as 1.
As noted above, these experiments were designed so that the
wild type protein (MA/CA) and the protein with the alternative
cleavage site had different sizes as both substrate and cleavage
product, which allowed us to mix the two substrates and carry
out the cleavage reaction in a single tube. Thus, the wild type
substrate,MA/CA (Fig. 1A), was included in each reaction as an
internal control to measure the relative cleavage rate. Fluores-
cence images of the cleavage reactions for theCA/SP1, SP1/NC,
and RT/IN and the resulting time course of the cleavage for all
of the substrates are shown in Fig. 4 (A and B), respectively.
When the cleavage rates were compared with that of the
MA/CA site, we observed significant differences in the rate of
cleavage for some of the different Gag and Gag-Pro-Pol cleav-
age sites (Fig. 4, B andC). As can be seen in Fig. 4C, the sites can
be grouped into those cleaved within 3-fold of the rate of
MA/CA and those that were cleaved much more slowly.
MA/CA andRT/IN have similar cleavage rates in the context of
Gag-Pro-Pol (9) and also similar rates in the context ofMA/CA
(Fig. 4C). SP1/NC has a 10-fold higher cleavage rate in its
homologous position, but when transposed the rate was slower
than MA/CA, but cleavage was still detectable (Fig. 4C).
CA/SP1 is cleaved slowly, but this rate is dictated by prior
removal of the NC domain by cleavage at SP1/NC; when the
SP1/NC cleavage site is blocked then CA/SP1 cleavage occurs
at a rate that is similar to MA/CA (3), which was also the case
when the site is placed at the MA/CA site (Fig. 4C). NC/SP2,
TR/PR, and PR/RT are all cleaved slowly in the context of Gag
andGag-Pro-Pol (3, 9, 10) and were cleaved poorly when trans-
posed into theMA/CA site (Fig. 4C). The most anomalous rate
is that of SP2/p6, which is similar to MA/CA in the context of
Gag (3) but was cleaved very poorly when the site was trans-
posed (Fig. 4C). However, the magnitude of the decrease of the
rate of cleavage of SP1/NCand SP2/p6 is similar comparedwith
the rate of cleavage in Gag, suggesting that especially for these
two sites their context in Gag plays a significant role in enhanc-
ing the rate of cleavage.
Inhibitor Resistance Mutations in HIV-1 Protease Can
Change Processing Site Preferences—The presence of multiple
mutations in the protease region can reduce binding affinity to
protease inhibitors leading to resistance to the protease inhib-
itors. It is possible that these protease variants also alter sub-
strate specificity (36, 37). To see whetherMDRHIV-1 protease
variants can affect the order of the rates of the Gag and Gag-
Pro-Pol cleavage, we tested two MDR HIV-1 protease variants
in our protease assay: PRG2 containing amino acid substitutions
L10I, G48V, I54V, L63P, andV82A; andPRG4 containing amino
acid substitutions L10I, L63P, A71V,G73S, I84V, and L90M.As
shown in the Fig. 5, the PRG2 enzyme had relative rates of cleav-
age of the different substrates that were overall similar to the
wild type enzyme with the exception of the SP1/NC site, which
was cleaved at a six times faster rate than the MA/CA site and
now more similar to its rate in full-length Gag (3), and the
FIGURE 3. Effect of pH on proteolysis of MA/CA by HIV-1 PR. A, the labeling and proteolysis reactions of the substrate MA/CA were performed at pH 5.5,
6.0, 6.5, or 7.0 as described in Fig. 2A. Fluorescently labeled proteins were visualized by fluorescence imaging. Filled arrowheads indicate the substrate before
cleavage (MA/CA) and after cleavage (CA). B, the band intensity of the cleavage products, CA, shown in A was quantified and plotted as a function of the
time. C, cleavage rates were calculated using the time points in which the percentage amounts of the cleavage products are within the linear range (20%).
The slope value obtained from linear regression analysis was used to compare the cleavage rate among different pH levels.
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CA/SP1 site, which was cleaved moderately faster compared
with the MA/CA site. In contrast, the PRG4 variant resulted in
relative rates that were similar to those of the PRWT with the
exception of the RT/IN site, which was modestly reduced (Fig.
6). Thus, the two MDR proteases showed distinct but mostly
modest effects on substrate processing except for one of them
(PRG2) changing the relative rate of cleavage of one site (SP1/
NC) by 10-fold.
Chimeric Cleavage Site Composed of P4–P1 Amino Acids
from SP1/NC Site and P1–P4 Amino Acids from MA/CA Site
Selectively Abolishes Processing by HIV-1 Proteases—Both
MA/CA and SP1/NC sites are efficiently cleaved either in the
FIGURE 4. Processing of the Gag and Gag-Pro-Pol cleavage sites in the context of the MA/CA by PRWT. A, fluorescence images displaying the processing of the
CA/SP1, SP1/NC, and RT/IN sites in the heterologous MA/CA context are shown. The labeling and proteolysis reactions of the substrates were performed at pH 7.0 as
described in Fig. 2A. The MA/CA substrate was included in all of the cleavage reaction as an internal control, which allows direct comparison of cleavage rates between
the reactions. Filled arrowheads indicate MA/CA substrates containing the heterologous cleavage site and its cleavage product (CA), and open arrowheads indicate
MA/CA substrate and its cleavage product (CA). B, the percentage amounts of the cleavage products are shown over time. The standard deviation of the MA/CA site
is shown. C, cleavage rates of the processing sites within the Gag and Gag-Pro-Pol region are shown, relative to that of the MA/CA site, which was set at 1.
FIGURE 5. Processing of the Gag and Gag-Pro-Pol cleavage sites in the context of the MA/CA by PRG2. A, fluorescence images depicting the processing of the
CA/SP1, SP1/NC, and RT/IN sites in the heterologous MA/CA context are shown. The labeling and proteolysis reactions of the substrates were performed at pH 7.0 as
described in Fig. 2A. Filled arrowheads indicate MA/CA substrates containing the heterologous cleavage site and its cleavage product (CA), and open arrowheads
indicate MA/CA substrate and its cleavage product (CA). B, the percentage amounts of the cleavage products are shown over time. The standard deviation of the
MA/CA site is shown. C, cleavage rates of the processing sites within the Gag and Gag-Pro-Pol region are shown, relative to that of the MA/CA site, which was set at 1.
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context of the Gag polyprotein or in the context of the peptide
substrates, and these two sites were differentially recognized by
the wild type and two MDR proteases (Figs. 4–6). Thus, to
explore substrate specificity further, we investigated two chi-
meric substrates: SP1/NC P4–1 and SP1/NC P1–4. SP1/NC
P4–1 harbors P4–P1 derived from the SP1/NC site and P1–
P4 derived from the MA/CA site, whereas SP1/NC P1–4
contains P4–P1 derived from the MA/CA site and P1–P4
derived from the SP1/NC site. When these two chimeric sub-
strates were tested for cleavage efficiency by the three different
proteases, PRWT, PRG2, and PRG4, the chimeric substrates were
poorly cleaved by the all of the enzymes (Fig. 7, A and B). The
one exception was the SP1/NC P1–4 chimera, which was
cleaved faster than theMA/CA site but slower than the SP1/NC
site, when cleaved by the PRG2 enzyme. Although the P1 to P4
amino acids accounted for much of the enhanced efficiency of
the PRG2 protease for the SP1/NC site, in most cases the chi-
meras were poor substrates compared with their parental
sequences, implying that the amino acids on either side of the
scissile bond are interdependent for optimal processing.
Substrate specificity of theHIV-1 protease is determined by a
number of elements responsible for the molecular interactions
between protease and substrates. Thus, it is possible that
changes in themolecular interactions between protease and the
substrate caused by the alterations made in the SP1/NC P4–1
create a substrate that cannot be cleaved by theHIV-1 protease.
To explore this possibility, the total number of hydrogen bonds
and the van der Waals contacts between the protease and the
chimeric substrates (P4–P4) within the structure of the pro-
tease-substrate complexes were analyzed using previously
determined structures (16) and models of the chimeric sub-
strates derived from these structures. The van derWaals inter-
actions reflect the favorable protease-substrate contacts caused
by local packing in the hydrophobic binding groove, whereas
hydrogen bonds play a crucial role in substrate specificity (15,
16). When we compared the results from the chimeric sub-
strates to those from the parental substrate sites MA/CA and
SP1/NC, the SP1/NC P4–1 had fewer total hydrogen bonds
(Fig. 7C) and less van der Waals contact potential than the
parental substrates (Fig. 7D). The SP1/NC P1–4 substrate
exhibited relatively high scores in these measures of molecular
interactions between the protease and the substrate compared
with the other substrates (Fig. 7, C and D); however, it was
cleaved poorly by the PRWT and PRG4 proteases (Fig. 7, A and
B). The structural data seem to reflect these cleavage patterns
only when both the substrate dynamics within the binding site
and the impact of the residues surrounding the processing sites
on the protease-substrate interactions are incorporated into
the molecular modeling studies.
DISCUSSION
The HIV-1 PR has been an important target for a successful
group of HIV-1 inhibitors because of its essential role in the
proteolytic processing of HIV-1 Gag andGag-Pro-Pol polypro-
tein for the formation of infectious virus. However, much still
remains to be learned about the determinants of HIV-1 PR
specificity in the context of the processing/assembly cascade.
Most of our knowledge regarding PR specificity has come from
the studies using peptides as substrates representing the Gag
and Gag-Pro-Pol cleavage sites, which cannot account for pos-
sible elements residing outside of the local cleavage site
sequences, P4–P4. There has been a disagreement between
FIGURE 6. Processing of the Gag and Gag-Pro-Pol cleavage sites in the context of the MA/CA by PRG4. A, fluorescence images displaying the processing
of the CA/SP1, SP1/NC, and RT/IN sites in the heterologous MA/CA context are shown. The labeling and proteolysis reactions of the substrates were performed
at pH 7.0 as described in Fig. 2A. Filled arrowheads indicate MA/CA substrates containing the heterologous cleavage site and its cleavage product (CA), and
open arrowheads indicate MA/CA substrate and its cleavage product (CA). B, the percentage amounts of the cleavage products are shown over time. The
standard deviation of the MA/CA site is shown. C, cleavage rates of the processing sites within the Gag and Gag-Pro-Pol region are shown, relative to that of the
MA/CA site, which was set at 1.
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the order of cleavage obtained from the studies with peptide
substrates and the order of cleavage in the context of full-length
Gag polyprotein. Moreover, the order of cleavage of various
cleavage sites ranked by different studies with peptide sub-
strates is not consistent (19, 21, 22). One discrepancy among
these studies is the length of the peptide used, which suggests
that the local environment surrounding the heptapeptide cleav-
age site may play a role in determining substrate specificity of
the HIV-1 PR, although methodological differences may also
account for the reported rate differences. Thus, in an attempt to
explore the question of context further, we performed a com-
parative analysis of the effect of context onHIV-1 processing by
introducing Gag and Gag-Pro-Pol cleavage sites into the heter-
ologous context of the Gag MA/CA cleavage site. By labeling
the protein substrate, MA/CA, with a FlAsH reagent that
binds the tetracysteine motif introduced within the NTD
region of CA, we were able to detect andmeasure proteolysis of
the substrate by the HIV-1 PR. In addition, we were able to
manipulate the length of both the upstream and downstream
segments of the products to allow two substrates and their
labeled products to be resolved together by SDS-PAGE, which
enabled us to run the wild type sequence as an internal control/
standard in each reaction. Replacing the MA/CA cleavage site
with cleavage sites from the Gag and Gag-Pro-Pol polyproteins
resulted in similarities and differences in the expected rates of
cleavage, revealing that the context surrounding at least three
of the cleavage sites plays amajor role in determining the rate of
cleavage by the HIV-1 PR. In addition, the use of MDR HIV-1
PR variants, PRG2 and PRG4, also selectively affected the rates of
cleavage. The use of a fluorescent tag has also allowed us to
develop a protease assay based on cleavage of a folded protein
using fluorescence anisotropy, which is amenable to large scale
screens directed at inhibitors of either the protease or the
substrate.3
Our goal in using a folded protein substrate was to be able to
examine the cleavage site requirements in the context of the
larger protein. We found that with the large MA/CA protein
substrate, the optimal pH for cleavage by the protease was
between 6.5 and 7.0. This result differs from earlier studies
using peptides as substrates, which showed an optimum pH
below 6 for proteolysis (3, 17, 38–40). In an in vitro assay using
radiolabeled Gag polyprotein as a substrate, Pettit et al. (3)
observed that the CA/SP1 site was cleaved about 20-fold faster
at pH 5 compared with a reaction run at pH 7, measured as the
rate relative to the MA/CA site. For synthetic peptide sub-
strates, the Km values were higher at pH 7 relative to lower pH,
suggesting that peptides interact less well with the HIV-1 pro-
tease at pH 7 than at lower pH (38). The higher rate of cleavage
at neutral pH that we observed is more consistent with the
expectation that the pH in the virion should be the same as that
in the cell.
Our previous work looking at the relative rates of the cleav-
age in the Gag and Gag-Pro-Pol polyprotein (3, 9) provide a
context for interpreting the rates of cleavage of the same sites
when placed in the MA/CA site. We propose that three phe-
nomena are at work in defining the rates of cleavage when the
sites are placed in this heterologous site. First, the rate of cleav-
age for one set of sites is largely determined by the sequence of
the cleavage site such that the rate of cleavage is similar at the
3 S.-K. Lee, C. A. Schiffer, and R. Swanstrom, manuscript in preparation.
FIGURE 7. Reduced processing of the chimeric cleavage sites composed of the amino acids from the SP1/NC and MA/CA sites. A, the percentage amount
of the cleavage product of the MA/CA, SP1/NC, SP1/NC P4 –1, and SP1/NC P1– 4 sites processed by PRWT, PRG2, or PRG4 are shown as a function of time. The
SP1/NC P4 –1 contains P4 –P1 residues derived from the SP1/NC site and P1–P4 residues derived from the MA/CA site. The SP1/NC P1– 4 contains P4 –P1
residues derived from the MA/CA site and P1–P4 residues derived from the SP1/NC site. The amino acid sequence of the cleavage sites (MA/CA, SP1/NC,
SP1/NC P4 –1, and SP1/NC P1– 4) is shown. B, cleavage rates of the MA/CA, SP1/NC, SP1/NC P4 –1, and SP1/NC P1– 4 sites relative to that of the MA/CA site
are shown. C, number of total hydrogen bonds between the protease and substrates. D, calculated van der Waals contact potentials between the protease and
substrates.
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homologous site and in the MA/CA site. A corollary of this
assumption is that theMA/CA site itself is somewhat neutral in
terms of the contribution of context.We have observed that the
addition of a glycine spacer (three glycines) upstream and
downstream of the MA/CA site has a uniform effect on all
cleavage sites in modestly reducing the rate of cleavage, sug-
gesting that there is no significant contribution of context to a
specific sequence at the MA/CA site.4 Thus, we interpret the
similar cleavage rates of MA/CA, RT/IN, NC/SP2, TF/PR, and
PR/RT in both homologous and heterologous sites as being
determined largely by the cleavage site sequence itself. Hence, it
should be possible to significantly increase the rate of cleavage
of the slowly cleaved sequences with changes in the cleavage
site sequence itself, a possibility we are exploring.
Second, the rate of cleavage is negatively regulated in the
homologous site such as the CA/SP1 site, which is known to be
under negative regulation in its homologous site. When placed
in the MA/CA site, its rate of cleavage was consistent with
removal of that negative regulation. In its homologous context,
the CA/SP1 site is cleaved very slowly. Placement of this site in
the MA/CA context increased its rate of cleavage to 40% of
the rate of cleavage of the MA/CA site. Similar increases in the
rate of cleavage occur either when the downstream SP1/NC
cleavage is blocked or when the pH is lowered (3), although in
another study the enhanced rate did not result in complete
cleavage at the CA/SP1 site in either both transfected cells or
virus particles (6). In addition, the amino acid sequences at the
CA/SP1 boundary have been predicted to adopt an -helical
structure (41); however, the NMR structure of a fragment
including the C-terminal domain of capsid through the NC
domain did not reveal an -helical structure at the CA/SP1
boundary because of the flexibility of this region (42). It is pos-
sible that the amino acids at the CA/SP1 boundary region
undergo a conformational change upon the initial cleavage at
the SP1/NC site to function as a negative regulator on the cleav-
age at the CA/SP1 site, although the mechanism is still unclear.
Finally, we interpret two sites as being under local positive
regulation in their homologous sites. Both the SP1/NC site and
the SP2/p6 site are cleaved at significantly slower rates in the
heterologous context of the MA/CA protein than in their
homologous sites. Curiously, both are at the C-terminal end of
a spacer peptide, and both play significant roles in the interac-
tion with viral RNA (4, 43–45).
The SP2/p6 site is efficiently cleaved in its homologous site
(3), and in the p15 (NC/SP2/p6) intermediate, its cleavage is
strongly enhanced by binding of RNA to NC (4, 7). However,
out of this context, i.e.when placed at theMA/CA site, the rate
of cleavage is very slow, analogous to the rate of cleavage in the
absence of RNA. It is unlikely that RNA serves as a cofactor for
the protease in the cleavage of the SP2/p6 site. The alternative
explanation is that RNA binding to NC promotes a conforma-
tional change that greatly enhances the presentation of the
cleavage site sequence in its homologous context. It has been
shown that it is the binding of RNA to NC that is important for
this rate enhancement; however, the nature of the conforma-
tional change induced by RNA binding is not known. Based on
this argument, the SP2/p6 site alone is suboptimal for cleavage,
as seen when placed in the MA/CA site, but a local conforma-
tion is able to overcome the suboptimal sequence context to
enhance recognition and/or cleavage by the viral proteasewhen
in its homologous context of NC/SP2/p6.
The SP1/NC also appears to be under positive regulation in
its homologous site. This site is the first site cleaved in Gag, and
its rate of cleavage in full-length Gag is significantly faster than
the rate of cleavage of the MA/CA site, in contrast to its rate of
cleavage when this site is placed at theMA/CA site. It should be
noted that in these experiments the sequence of the NL4-3
cleavage site was used, and it contains isoleucine at the P1
position instead of methionine. The more common P1 methi-
onine increases the rate of cleavage of the SP1/NC site several-
fold when placed in this heterologous site,5 but it is still well
below themuch higher relative cleavage rate seen in the homol-
ogous site. In either form the cleavage rate of the SP1/NC site in
the context of the MA/CA was far less than that in its original
context, which is consistent with an earlier study demonstrated
by Tritch et al. (5) using in vitro translated Gag proteins. Cleav-
age at the SP1/NC site is important for the maturation of viral
RNA from a low stability dimer to the high stability dimer asso-
ciated with the mature virus particle (46). Although the failure
of NC to bind RNA greatly reduces the rate of cleavage of the
SP2/p6 site, the failure to bind RNA does not affect the gener-
ation of the p15 intermediate, suggesting that the rapid cleavage
at the SP1/NC site is not dependent on NC binding to RNA.
Thus, the nature of the positive regulator that makes the
SP1/NC site the most rapidly cleaved site in either Gag or Gag-
Pro-Pol is unknown.
With the MDR HIV-1 PR variants PRG2 and PRG4, we
observed two types of changes with respect to the relative rates
of cleavage. One type of change resulted in a modest, 2–3-fold
increase or decrease in the rate of cleavage relative to the
MA/CA site. In our experimental design we measure rates rel-
ative to the wild type MA/CA site. If the mutant proteases had
a specific change in the rate of cleavage at the MA/CA site, we
would not be able to discern this effect versus a change at
another site. Thus, it is difficult to interpret these relatively
small changes with respect to mechanism. However, there was
an 10-fold relative increase by PRG2 in the relative rate of
cleavage of the SP1/NC site, suggesting a significantly enhanced
interaction between this site and the MDR protease. An exam-
ination of the number of hydrogen bonds or van der Waals
interactions did not provide an obvious explanation for this
change. It is possible that the mutant protease interacts with
substrates in a way that at least in part compensates for the
positive regulatory element that affects the rate at the homolo-
gous site. We speculate that the P1 to P4 residues of the
SP1/NC site contribute to the significant proportion of the pos-
itive interactions with the PRG2 mutant protease (Fig. 7). The
use of either SP1/NC or MA/CA half-sites also showed that
neither half-site when paired with the complementary half-site
was significantly active as a substrate for the wild type enzyme.
4 M. Potempa, S.-K. Lee, C. A. Schiffer, and R. Swanstrom, manuscript in
preparation. 5 S.-K. Lee, M. Potempa, C. A. Schiffer, and R. Swanstrom, unpublished data.
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Therefore, the chimeric substrates composed of two half-sites
derived from the SP1/NC andMA/CA sites are antagonistic in
their interaction with the protease, and effects across the scis-
sile bond caused by the substitutions must alter the interaction
of each half-site within the enzyme.
In this report, we demonstrate the importance of the context
surrounding cleavage sites on Gag processing by using a heter-
ologous context, the MA/CA, suggesting that interactions
between the PR residues and the substrates are not confined
within the active site of the protease. We suggest that context
plays a different role for different sites, either being relatively
neutral, providing negative regulation, or providing positive
regulation. Even within a cleavage site sequence, the two half-
sites can play a positive effect with each other in determining
the rate of cleavage. These long range features of the regulation
of cleavage rates cannot be addressed using peptide substrates
and therefore point to the need to use Gag protein substrates to
explore the role of context in regulating cleavage rates.
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